SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $35 | $38 | $26 | $340 |
| - Cash | $9 | $57 | $15 | $33 |
| + Debt | $5 | $6 | $6 | $9 |
| Enterprise Value | $31 | -$13 | $17 | $315 |
| Revenue | $1 | $2 | $24 | $61 |
| % Growth | -40.9% | -90.6% | -60.7% | – |
| Gross Profit | -$3 | -$2 | $21 | $59 |
| % Margin | -262.4% | -67.3% | 86.2% | 97.3% |
| EBITDA | -$29 | -$38 | -$15 | -$15 |
| % Margin | -2,192.5% | -1,703.1% | -63.3% | -25% |
| Net Income | -$34 | -$42 | -$19 | -$17 |
| % Margin | -2,579% | -1,884.5% | -78.4% | -28.2% |
| EPS Diluted | -3.68 | -7.64 | -4.31 | -6.3 |
| % Growth | 51.8% | -77.3% | 31.6% | – |
| Operating Cash Flow | -$34 | -$25 | -$23 | $2 |
| Capital Expenditures | -$0 | -$0 | -$2 | -$11 |
| Free Cash Flow | -$35 | -$25 | -$26 | -$9 |